Open AccessClinical relevance of circulating MACC 1 and S100A4 transcripts for ovarian cancer
Author(s) -
Link Theresa,
Kuhlmann Jan Dominik,
Kobelt Dennis,
Herrmann Pia,
Vassileva Yana D.,
Kramer Michael,
Frank Kerstin,
Göckenjan Maren,
Wimberger Pauline,
Stein Ulrike
Publication year - 2019
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12484
Subject(s) - ovarian cancer , clinical significance , debulking , medicine , metastasis , stage (stratigraphy) , biomarker , liquid biopsy , biopsy , oncology , tumor debulking , cancer , chemotherapy , cancer research , biology , paleontology , biochemistry
Metastasis‐associated in colon cancer 1 ( MACC 1) and S100 calcium‐binding protein A4 (S100A4) are prominent inducers of tumor progression and metastasis. For the first time, we systematically tracked circulating serum levels of MACC 1 and S100A4 transcripts in the course of surgery and chemotherapy and analyzed their clinical relevance for ovarian cancer. MACC 1 and S100A4 transcripts were quantified in a total of 318 serum samples from 79 ovarian cancer patients by RT ‐ qPCR and digital droplet PCR , respectively. MACC 1 and S100A4 transcripts were significantly elevated in serum of ovarian cancer patients, compared to healthy controls ( P = 0.024; P < 0.001). At primary diagnosis, high levels of MACC 1 or S100A4 correlated with advanced FIGO stage ( P = 0.042; P = 0.008), predicted suboptimal debulking surgery and indicated shorter progression‐free survival ( PFS ; P = 0.003; P = 0.001) and overall survival ( OS ; P = 0.001; P = 0.002). This is the first study in ovarian cancer to propose circulating MACC 1 and S100A4 transcripts as potential liquid biopsy markers.